Arechar healthcare, one of the leading manufacturers of the world, reported the launch of Albumin Bound Paclitaxel, under the brand name Abra-Bound. It is indicated for the treatment of metastatic breast cancer, lung cancer, and pancreatic cancer. In the oncology sector, the incidence of diseases is increasing rapidly, due to the inaccessibility and unaffordability of pharmaceutical products. This is the major concern behind manufacturing and launching efficacious products in the field of Pharma.
“Albumin Bound Paclitaxel is an injectable formulation of Paclitaxel that kills cancer cells. Keeping in mind the condition of cancer patients and their families, I am glad to introduce Abra-Bound, protein-bound paclitaxel which can be used to treat patients with breast cancer, lung cancer, and pancreatic cancer when administered under the doctor’s supervision,” said Mr. Harpreet Singh. “I, along with my company and its employees, work every day to maintain a leadership position in the pharmaceutical industry and serve the human lives with the best treatment options and solutions.”
“Our mission is not limited to manufacturing medicines, rather it focuses on the health of patients globally,” he added.
Albumin Bound Paclitaxel, also known as nanoparticle albumin-bound paclitaxel or nab-paclitaxel is a formulation of Paclitaxel. It is an injectable drug used in the treatment of metastatic breast cancer, lung cancer, and pancreatic cancer. Albumin Bound Paclitaxel is a combination of Paclitaxel (Mitotic inhibitor) and Albumin (Delivery vehicle). It was firstly in 2005 in the United States for breast cancer. Later, it was approved by FDA for the treatment of advanced pancreatic cancer.
Abra-Bound is an injectable drug, indicated to patients having metastatic breast cancer, lung cancer, and pancreatic cancer. It is available in the strength of 100 mg. Abra-Bound should be administered in patients exactly as the healthcare provider prescribes (according to the medical condition and the body requirements). The active ingredient of Abra-Bound is Paclitaxel.
About Arechar Healthcare
Arechar Healthcare is one of the largest leading manufacturers of life-saving drugs, working to serve the patients with the best and approved life-saving drugs at an affordable range of prices. It has attained an authoritative position worldwide in the field of Pharma. It has successfully extended its reach globally and is working with immense insight into humanity. Very few manufacturers possess the drive and determination that the Arechar Healthcare Team has displayed, ever since it started. Focussing on the accessibility and efficacy of life-saving drugs, Arechar Healthcare aims to strengthen the healing and treatment process, with a major focus on oncology care and other diseases that threaten human lives.
Related hot topics
Novartis PLUVICTO™ for Prostate Cancer Becomes the First Targeted Radioligand Therapy
Pluvicto is a targeted radioligand therapy for progressive PSMA-positive metastatic prostate cancer.
Arechar Healthcare provides independent and precise information about prescription drugs with the related news and press releases. This content is displayed for informational purposes only and is not intended to be an alternative for any medical advice/prescription or treatment. Do not delay or ignore any medical treatment owing to something you’ve read or seen on this website. Also, this website offers links to other websites, enabling the viewers to directly switch to that website for detailed information or accurate references. Thus, Arechar is not responsible for the content displayed on the linked websites or the content of the links in the linked website.